Immunotherapy as a First Treatment vs After Chemotherapy — What Actually Decides the Order

Yes, order matters — but not in a single fixed way. Whether immunotherapy comes first or after chemotherapy depends on your cancer type and biomarker results, not on general preference. Using it in the guideline-supported order gives it the best chance to perform as intended for your specific cancer. Using it outside that order is not automatically better, and it is not typically what your oncology team will offer first.

This page assumes immunotherapy is genuinely on the table for your cancer. Most cancer patients are not candidates for immunotherapy at all, at any point in their treatment — eligibility is confirmed by biomarker testing and cancer type, not by asking for it.

Immunotherapy is used first-line when your specific cancer type has an approved indication for it and your biomarker results support upfront use, before any chemotherapy. This commonly means a supportive PD-L1 expression level, an MSI-High or dMMR result, or a similarly relevant marker, depending on the cancer. It applies to a growing list of cancers, including certain lung, kidney, bladder and skin cancers, and it can be used either as immunotherapy on its own or combined with chemotherapy from the very first cycle.

First-line combinations are their own recognised approach, not a compromise — for several cancers, giving immunotherapy and chemotherapy together from the start is the guideline-supported option, chosen because the two work through different mechanisms.

Immunotherapy is used second-line when your cancer type doesn't carry a first-line approval for it, when biomarker results didn't support upfront use, or when the initial chemotherapy stopped working or wasn't well tolerated. In this setting, immunotherapy becomes an option once your oncologist confirms the cancer has progressed on the earlier treatment and reassesses your current biomarker status and overall fitness.

Second-line does not mean a lesser option — for cancers where it is the guideline-supported line of therapy, it remains the recommended next step rather than a fallback.

The decision is made by weighing several factors together, not by applying one rule to everyone. Your medical oncology team looks at your exact cancer type and stage, your biomarker or genetic test results, any treatment you've already received and how you responded to it, your overall fitness and any other health conditions, and what current oncology guidelines recommend for your specific situation.

• Cancer type and subtype — the single biggest factor; approvals for first-line use are granted cancer by cancer, not as a blanket rule.
• Stage at diagnosis — sequencing options can differ meaningfully between earlier and more advanced stages of the same cancer.
• Biomarker and genetic test results — PD-L1 expression, MSI/dMMR status, tumour mutational burden and similar markers, tested before the decision is made, not assumed.
• Prior treatment and response — what you've already had, and whether it worked, is reassessed rather than carried forward as an assumption.
• Performance status and comorbidities — overall fitness affects which treatment line is realistic to pursue next.
• Current guideline recommendations — NCCN- and ASCO-aligned protocols for your specific cancer, reviewed at the time of your decision.
• Your own goals and preferences — discussed openly, including practical considerations such as treatment access and insurance coverage.

Choosing not to pursue a further treatment line — whether that means declining second-line immunotherapy after chemotherapy, or stepping back from active treatment altogether — is a legitimate choice for some patients. This is particularly true when the expected benefit of another line is genuinely uncertain for your situation, or when your goals have shifted toward comfort and quality of life.

This decision belongs to you and your family, made with your oncology team's honest input on what a given treatment line can and cannot realistically achieve for your specific cancer. Supportive and palliative care remain fully available whether or not further systemic treatment is chosen, and the decision can be revisited at any point.

• If immunotherapy is being offered after surgery rather than for existing disease, Immunotherapy After Surgery: Why It Is Given When the Tumour Is Gone explains that separate use case.
• If you're weighing whether to pursue the next line at all, Can I Refuse Immunotherapy? What Happens If You Decline lays out that option honestly, alongside the alternatives.
• For the more hopeful question behind a sequencing decision, What Is a Durable Response, and Could It Happen to Me? explains what a long-lasting response actually means.
• For the full picture of immunotherapy at CION — how it's delivered, monitored and managed — see our immunotherapy hub.

Still not sure how any of this applies to your own diagnosis and treatment history? Book a free consultation and a medical oncologist will walk through it with you.